《科學》雜誌公佈了2023年度十大科學突破，將胰高糖素樣肽-1（GLP-1）受體激動劑的開發以及今年發現的可緩解肥胖相關健康問題的藥物列為年度突破之首。
Science and Technology Daily, Beijing, December 14 (Reporter Zhang Jiaxin) On the 14th, "Science" magazine announced the top ten scientific breakthroughs in 2023, including the development of glucagon-like peptide-1 (GLP-1) receptor agonists and this year's The discovery of a drug that alleviates obesity-related health problems tops the list of breakthroughs of the year.
減肥和超重一直是科學和公共衛生領域具有挑戰性的議題。導致肥胖的原因有很多，且有危及生命的風險。然而，在減肥藥物治療歷程中，對超重的污名化始終是一個不容忽視的問題，其導致人們總是將超重與一個人的意志薄弱，而不是與生物化學相關因素聯繫在一起。
Weight loss and overweight have always been challenging issues in science and public health. Obesity has many causes and can be life-threatening. However, in the process of weight loss drug treatment, the stigma of being overweight is always a problem that cannot be ignored, which leads people to always associate being overweight with a person's weak will rather than with biochemical factors.
現在，一種針對減肥的新藥物療法已經出現，並顯示出更多令人振奮的結果。今年，兩項里程碑式的臨床試驗進一步表明，最初是為了治療糖尿病而開發的GLP-1受體激動劑，產生了比後來發現的減肥功效更有意義的健康益處。目前研究人員正在進行幾項試驗，調查它們在治療藥物成癮、阿茲海默症和帕金森氏症中的效果。
Now, a new drug treatment for weight loss has emerged and is showing even more promising results. This year, two landmark clinical trials further showed that GLP-1 receptor agonists, originally developed to treat diabetes, produce more meaningful health benefits than the weight loss benefits later discovered. Researchers are currently conducting several trials investigating their effectiveness in treating drug addiction, Alzheimer's disease and Parkinson's disease.
《科學》雜誌主編霍爾登·索普在一篇相關社論中寫道：「儘管GLP-1受體激動劑前景看好，但它們提出的問題比回答的問題要多得多，而這是真正突破的標誌。”
Science editor-in-chief Holden Thorpe wrote in a related editorial: "While GLP-1 receptor agonists are promising, they raise more questions than they answer, and this is really A sign of breakthrough.”
相關評論文章認為，GLP-1藥物的開發將推動人們就肥胖問題展開討論，這有助於減少對體重超重的污名化。不過，評論文章也指出人們對這些藥物的成本、可近性、相關副作用以及可能需要無限期服用的擔憂。醫生也擔心不肥胖或不超重的人會尋求GLP-1藥物來達到快速減肥的目的。
Related review articles believe that the development of GLP-1 drugs will promote discussions on obesity, which will help reduce the stigma of being overweight. However, the review article also noted concerns about the cost, accessibility, associated side effects and the potential need to take these drugs indefinitely. Doctors are also concerned that people who are not obese or overweight will seek GLP-1 drugs to achieve rapid weight loss.
年度科學突破榜單還包括：一種可能減緩阿茲海默症患者大腦神經退化病變的抗體療法；發現地表以下的天然氫源；推動全球機構對早期職業科學家的待遇進行系統性改變；證實了在美國新墨西哥州一個古老湖泊中發現的人類足跡的古老性；地球重要的碳泵正在放緩；大規模黑洞合併產生的星際信號；人工智能輔助天氣預報的發展；新的瘧疾疫苗；E級超算的部署。
The annual list of scientific breakthroughs also includes: An antibody therapy that may slow neurodegenerative changes in the brains of Alzheimer's patients; Discovering a natural source of hydrogen below the Earth's surface; Pushing for systemic changes in the treatment of early career scientists by global institutions; Proving that The antiquity of human footprints found in an ancient lake in New Mexico, USA; Earth's vital carbon pump is slowing down; Interstellar signals from massive black hole mergers; Development of artificial intelligence-assisted weather forecasting; New malaria vaccine; E-class super Calculated deployment.
撥打電話